NASDAQ:EXAS

Exact Sciences Stock Forecast, Price & News

$130.04
-0.48 (-0.37 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$127.22
Now: $130.04
$131.04
50-Day Range
$116.57
MA: $129.07
$140.21
52-Week Range
$67.31
Now: $130.04
$159.54
Volume779,583 shs
Average Volume1.75 million shs
Market Capitalization$21.99 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.64
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype MAP, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Exact Sciences logo

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:EXAS
CUSIP30063P10
Phone608-535-8815
Employees4,800
Year Founded1995

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$876.29 million
Book Value$17.62 per share

Profitability

Net Income$-83,990,000.00

Miscellaneous

Market Cap$21.99 billion
Next Earnings Date5/4/2021 (Confirmed)
OptionableOptionable

Headlines

Is EXACT Sciences (EXAS) Stock A Buy or Sell?
March 29, 2021 |  finance.yahoo.com
Is It Too Late to Buy EXACT Sciences (EXAS) Stock?
March 23, 2021 |  finance.yahoo.com
First Week of EXAS May 21st Options Trading
March 19, 2021 |  nasdaq.com
Exact Sciences Corporation Rings the Closing Bell
February 24, 2021 |  nasdaq.com
Why Exact Sciences Stocks Is Trading Lower Today
February 17, 2021 |  benzinga.com
Exact Sciences Announces Fourth Quarter 2020 Results
February 16, 2021 |  finance.yahoo.com
See More Headlines

MarketRank

Overall MarketRank

1.76 out of 5 stars

Medical Sector

190th out of 2,025 stocks

Commercial Physical Research Industry

4th out of 42 stocks

Analyst Opinion: 3.4Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$130.04
-0.48 (-0.37 %)
(As of 04/16/2021 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EXAS News and Ratings via Email

Sign-up to receive the latest news and ratings for EXAS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Exact Sciences (NASDAQ:EXAS) Frequently Asked Questions

Is Exact Sciences a buy right now?

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Exact Sciences in the last year. There are currently 3 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Exact Sciences stock.
View analyst ratings for Exact Sciences
or view top-rated stocks.

What stocks does MarketBeat like better than Exact Sciences?

Wall Street analysts have given Exact Sciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Exact Sciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Exact Sciences' next earnings date?

Exact Sciences is scheduled to release its next quarterly earnings announcement on Tuesday, May 4th 2021.
View our earnings forecast for Exact Sciences
.

How can I listen to Exact Sciences' earnings call?

Exact Sciences will be holding an earnings conference call on Tuesday, May 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Exact Sciences' earnings last quarter?

Exact Sciences Co. (NASDAQ:EXAS) issued its quarterly earnings data on Monday, February, 15th. The medical research company reported ($2.79) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by $2.60. The medical research company had revenue of $466.34 million for the quarter, compared to analyst estimates of $465.98 million. Exact Sciences had a negative trailing twelve-month return on equity of 11.71% and a negative net margin of 25.27%.
View Exact Sciences' earnings history
.

How has Exact Sciences' stock been impacted by Coronavirus?

Exact Sciences' stock was trading at $57.82 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, EXAS stock has increased by 124.9% and is now trading at $130.04.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for EXAS?

14 equities research analysts have issued 12 month price objectives for Exact Sciences' stock. Their forecasts range from $92.00 to $226.00. On average, they expect Exact Sciences' share price to reach $150.33 in the next year. This suggests a possible upside of 15.6% from the stock's current price.
View analysts' price targets for Exact Sciences
or view top-rated stocks among Wall Street analysts.

Who are Exact Sciences' key executives?

Exact Sciences' management team includes the following people:
  • Mr. Kevin T. Conroy, Chairman, Pres & CEO (Age 55, Pay $1.82M)
  • Mr. Jeffrey T. Elliott CFA, Chief Financial Officer (Age 43, Pay $701.77k)
  • Ms. Ana Hooker, Sr. VP of Operations (Age 55, Pay $627.49k)
  • Mr. D. Scott Coward, Chief Admin. Officer, Sr. VP, Gen. Counsel & Sec. (Age 56, Pay $741.87k)
  • Mr. Jake Orville, Sr. VP of Pipeline (Age 47, Pay $769.63k)
  • Mr. G. Bradley Cole, Gen. Mang. of Precision Oncology (Age 65, Pay $1.23M)
  • Mr. Gary Frings, Chief Information Officer
  • Dr. Scott C. Johnson Ph.D., Chief Science Officer and Sr. VP of R&D
  • Ms. Megan Jones, Associate Mang. of Investor Relations
  • Mr. Tim Caprez, Chief Compliance Counsel & VP

What is Kevin T. Conroy's approval rating as Exact Sciences' CEO?

141 employees have rated Exact Sciences CEO Kevin T. Conroy on Glassdoor.com. Kevin T. Conroy has an approval rating of 97% among Exact Sciences' employees. This puts Kevin T. Conroy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Exact Sciences' key competitors?

What other stocks do shareholders of Exact Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Exact Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), salesforce.com (CRM), PayPal (PYPL), Square (SQ), Advanced Micro Devices (AMD), The Walt Disney (DIS) and AbbVie (ABBV).

What is Exact Sciences' stock symbol?

Exact Sciences trades on the NASDAQ under the ticker symbol "EXAS."

Who are Exact Sciences' major shareholders?

Exact Sciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Scout Investments Inc. (0.09%), Thompson Investment Management Inc. (0.07%), Moody National Bank Trust Division (0.06%), Royal London Asset Management Ltd. (0.03%), DnB Asset Management AS (0.02%) and EFG Asset Management Americas Corp. (0.02%). Company insiders that own Exact Sciences stock include G Bradley Cole, Graham Peter Lidgard, Jacob A Orville, James Edward Doyle, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Mark Stenhouse, Sarah Condella, Scott C Johnson and Torsten Hoof.
View institutional ownership trends for Exact Sciences
.

Which major investors are selling Exact Sciences stock?

EXAS stock was sold by a variety of institutional investors in the last quarter, including Thompson Investment Management Inc., EFG Asset Management Americas Corp., Golden Green Inc., AdvisorNet Financial Inc, Pacer Advisors Inc., Moody National Bank Trust Division, and Valeo Financial Advisors LLC. Company insiders that have sold Exact Sciences company stock in the last year include Graham Peter Lidgard, Jacob A Orville, James Edward Doyle, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Sarah Condella, and Torsten Hoof.
View insider buying and selling activity for Exact Sciences
or view top insider-selling stocks.

Which major investors are buying Exact Sciences stock?

EXAS stock was bought by a variety of institutional investors in the last quarter, including Scout Investments Inc., DnB Asset Management AS, Polianta Ltd, Chicago Capital LLC, ERn Financial LLC, Phoenix Wealth Advisors, Royal London Asset Management Ltd., and FDx Advisors Inc..
View insider buying and selling activity for Exact Sciences
or or view top insider-buying stocks.

How do I buy shares of Exact Sciences?

Shares of EXAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Exact Sciences' stock price today?

One share of EXAS stock can currently be purchased for approximately $130.04.

How much money does Exact Sciences make?

Exact Sciences has a market capitalization of $21.99 billion and generates $876.29 million in revenue each year. The medical research company earns $-83,990,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis.

How many employees does Exact Sciences have?

Exact Sciences employs 4,800 workers across the globe.

When was Exact Sciences founded?

Exact Sciences was founded in 1995.

What is Exact Sciences' official website?

The official website for Exact Sciences is www.exactsciences.com.

Where are Exact Sciences' headquarters?

Exact Sciences is headquartered at 5505 ENDEAVOR LANE, MADISON WI, 53719.

How can I contact Exact Sciences?

Exact Sciences' mailing address is 5505 ENDEAVOR LANE, MADISON WI, 53719. The medical research company can be reached via phone at 608-535-8815 or via email at [email protected]


This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.